(Q35936942)

English

Review article: tegaserod -- the global experience

scientific article

In more languages

edit

Statements

instance of

scholarly article

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

Europe PubMed Central

title

Review article: tegaserod -- the global experience (English)

1 reference

stated in

Europe PubMed Central

PubMed publication ID

11 August 2017

1 reference

Chey WD

1

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

language of work or name

English

0 references

publication date

1 November 2004

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

published in

Alimentary Pharmacology & Therapeutics

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

volume

20 Suppl 7

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

page(s)

15-19

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

cites work

Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02181.X

retrieved

21 January 2018

A randomized, double-blind, placebo-controlled trial of tegaserod in female patients suffering from irritable bowel syndrome with constipation

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02181.X

retrieved

21 January 2018

Long-term safety of tegaserod in patients with constipation-predominant irritable bowel syndrome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02181.X

retrieved

21 January 2018

An Asia-Pacific, double blind, placebo controlled, randomised study to evaluate the efficacy, safety, and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02181.X

retrieved

21 January 2018

A double-blind, placebo-controlled, randomized study to evaluate the efficacy, safety and tolerability of tegaserod in patients with irritable bowel syndrome

1 reference

stated in

Crossref

reference URL

https://api.crossref.org/works/10.1111%2FJ.1365-2036.2004.02181.X

retrieved

21 January 2018

Identifiers

DOI

10.1111/J.1365-2036.2004.02181.X

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

Fatcat ID

release_mmgmmzdyrvedzdjis4wdud6yiu

1 reference

stated in

Fatcat

reference URL

https://api.fatcat.wiki/v0/release/mmgmmzdyrvedzdjis4wdud6yiu

retrieved

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

15521850

1 reference

stated in

Europe PubMed Central

PubMed publication ID

15521850

retrieved

11 August 2017

ResearchGate publication ID

8198488

0 references

(Q35936942)

Review article: tegaserod -- the global experience

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)